John McHutchison becomes CEO of Tune Therapeutics after $175 million funding. Tune develops epigenetic treatments to control gene expression without editing.

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced a major milestone Sunday — raising $175 million in a Series B funding round to support its ...

Tune Therapeutics in Durham, NC raises $175 million in Series B as Duke University startup begins clinical trial for hepatitis B drug ...

DURHAM, N.C. & SEATTLE-- (BUSINESS WIRE)--Today, leading epigenomic editing company Tune Therapeutics introduced two members to its leadership team: Chief Scientific Officer, Derek Jantz, Ph.D ...

DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Last week, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), leading epigenetic editing company Tune Therapeutics ...

The Tune Therapeutics results are the first published data showing successful CRISPR epigenome editing in non-human primates.

DURHAM, N.C. & SEATTLE, January 13, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, ...

A Durham firm is advancing what could become a new treatment, and potential cure, for hepatitis B.

DURHAM, NC and SEATTLE, WA– Nov 13, 2023 – Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV ...

DURHAM, N.C. & SEATTLE, March 04, 2025--Leading epigenome company Tune Therapeutics is proud to announce that veteran drug-development executive John McHutchison AO, MD will be its new CEO and ...

Tune Therapeutics' epigenetic editor represses HBV genes in cell lines in mice almost completely, setting the stage for clinical trials in humans.